Journal of Rheumatic Diseases

Table. 7.

Patients with cancer recurrence and progression

No. Sex/Age (yr) Cancer Stage DMARDs
before
cancer diagnosis
DMARDs
right after
cancer diagnosis
Cancer
treatment
DMARDs
before
recurrence
Relapse
time
(yr)
Cancer
treatment
after
recurrence
DMARDs
after
recurrence
FU
(yr)
Current
RA
treatment
1 M/72 Lung IV (T4aN0M0) MTX+LEF+HCQ Discontinuation C HCQ 1.7 C HCQ 2.6 Death
2 F/71 CBD III MTX+SSZ+HCQ Discontinuation S+C No DMARD 0.9 C No DMARD 1.2 FU loss
3 F/39 Cervix I MTX+ADA Switching→LEF+TC+HCQ S+C LEF+TC+HCQ 1.5 C LEF+HCQ 7.1 No DMARD
4 F/57 Colon III MTX+SSZ+HCQ Switching→ SSZ+HCQ S+C MTX+ADA 2.3 C No DMARD 6.6 No DMARD
5 M/50 CML Accelerated MTX+HCQ Discontinuation C No DMARD 2.4 C No DMARD 8.0 No DMARD
6 F/67 Stomach I MTX+LEF Discontinuation S ADA 2.1 S ADA 7.1 TCZ
7 F/66 Lung II MTX+LEF+HCQ Switching → HCQ S+C MTX+HCQ 1.3 C MTX+HCQ 4.4 MTX+HCQ
8 M/80 Bladder I TCZ Maintenance S MTX+LEF 0.7 S+C LEF 4.6 MTX

F: female, M: male, CBD: common bile duct, CML: chronic myelogenous leukemia, DMARDs: disease modifying antirheumatic drugs, MTX: methotrexate, LEF: leflunomide, TCZ: tocilizumab, ADA: adalimumab, HCQ: hydroxychloroquine, SSZ: sulfasalazine, S: surgical therapy, C: chemotherapy, FU: follow-up, RA: rheumatoid arthritis.

J Rheum Dis 2022;29:162~170 https://doi.org/10.4078/jrd.2022.29.3.162
© J Rheum Dis